Ert Pompe denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for ert pompe are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS May Deny ERT for Pompe Disease as "Not FDA-Approved"

A denial from Blue Cross Blue Shield citing "not FDA-approved" for enzyme replacement therapy in Pompe disease is, in most cases, a factually incorrect denial. ERT for Pompe disease has received FDA approval. When this denial code appears, it usually indicates one of the following: the specific product's NDC code was entered incorrectly on the claim; the plan's drug database has not yet been updated to reflect a newer approval or updated label; the diagnosis code on the claim does not match the FDA-approved indication; or the denial system misclassified the claim due to a formulary or coding error.

This type of denial is correctable and is among the most straightforward to reverse on appeal.

## Why This Denial Is Appealable

BCBS's own coverage policies require coverage of FDA-approved drugs for their FDA-approved indications. If the requested ERT product holds FDA approval for Pompe disease and the patient has a confirmed diagnosis, the insurer's stated denial basis is inconsistent with its own published standards. Providing the FDA label as evidence is the central task.

## Federal Appeal Framework

• Internal appeal: File within the deadline shown on the EOB or denial letter. Because the basis is a factual error, a concise, documentation-focused appeal is usually sufficient. Standard response time is 30 days; expedited (for clinical urgency) is 72 hours.
• External review (ACA §2719): If BCBS upholds the denial internally, request independent external review. The IRO will verify whether the denial basis — "not FDA-approved" — is factually accurate. The external-review window is typically four months from final internal denial.
• ERISA §503 (employer plans): Request the specific clinical or regulatory basis BCBS used to conclude the product is not FDA-approved. That document will clarify whether the error is in their drug database, the claim coding, or their coverage policy.

## Documentation to Gather

• FDA prescribing label: The current FDA-approved prescribing label for the specific ERT product, clearly showing the approved indication includes Pompe disease. This is Exhibit A.
• Claim coding verification: Ask the specialty pharmacy or infusion center to confirm the NDC code submitted and the ICD-10 diagnosis code, and verify both align with the FDA-approved indication.
• Diagnosis confirmation: Genetic mutation analysis (GAA gene) and/or enzyme activity assay establishing the Pompe disease diagnosis.
• BCBS drug policy: Pull the current BCBS medical or pharmacy policy for this ERT product. If it acknowledges FDA approval, attach it to the appeal and note the inconsistency with the denial.
• Prescriber letter: A brief letter from the treating physician confirming the product prescribed has FDA approval for the patient's confirmed diagnosis.

## Criteria-Mapping Structure

This appeal is simpler than most because it turns on a single factual question: does the product have FDA approval for this indication?

| Denial Basis | Corrective Documentation | |---|---| | Product not FDA-approved | [FDA prescribing label showing approved indication] | | Indication not covered | [Diagnosis confirmation matching FDA label indication] | | Coding inconsistency (if applicable) | [Corrected NDC and ICD-10 codes from pharmacy/prescriber] |

Attach the FDA label as a clearly labeled exhibit and reference it in the first paragraph of your appeal letter. Note clearly that the denial basis is factually inconsistent with the FDA approval record.